Biotech Values

[DewDiligence]

SGEN exercises option to co-develop tisotumab vedotin with GEN.CO:

https://globenewswire.com/news-release/2017/08/29/1101629/0/en/Genmab-and-Seattle-Genetics-to-Co-develop-Tisotumab-Vedotin-for-Solid-Tumors.html

Genmab A/S and Seattle Genetics, Inc. announced today that Seattle Genetics, Inc. has exercised its option to co-develop tisotumab vedotin. The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab vedotin at the end of Phase I clinical development. Tisotumab vedotin, an antibody-drug conjugate (ADC) targeting tissue factor, is currently being evaluated in Phase I/II clinical studies in solid tumors. Going forward, Genmab and Seattle Genetics will co-develop and share all future costs and profits for tisotumab vedotin on a 50:50 basis.